Takeda has shuffled certain key executive positions in the ICMEA (India, CIS, the Middle East and Africa) region where it hopes to sharpen its focus, while also emerging more agile as the integration with Shire advances.
Andrey Potapov, Area Head, ICMEA
Takeda Pharmaceutical Co. Ltd., which completed its acquisition of Shire PLC in January this year, appears to be rejigging its leadership in some key international market groupings that include India, the CIS and Africa, among others, as it readies to move full throttle towards integrating operations with Shire.
[Sidebar#SC124441]
Keep up with the top pharma business news of the week. On the go.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.